News articles about Chiasma (NASDAQ:CHMA) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chiasma earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 44.8556631239261 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Chiasma (NASDAQ CHMA) remained flat at $$1.65 on Tuesday. The company had a trading volume of 58,900 shares, compared to its average volume of 119,480. The company has a market cap of $40.23 and a price-to-earnings ratio of -1.41. Chiasma has a 1 year low of $1.25 and a 1 year high of $2.95.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
What are top analysts saying about Chiasma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chiasma and related companies.